HBSP (USA)
-
Terumo (C) (Spanish Version)
Godes, David B.; Egawa, Masako; Yamazaki, MayukaCase HBS-510S03MarketingPara maximizar su eficacia, los casos de color deben imprimirse en color. Este caso proporciona una información actualizada sobre la decisión de la empresa en cuanto a su estrategia de ventas para sus productos de EE.UU. catéter y el progreso del paquete de soluciones. También se analiza la expansión de la firma del "Pranex médica", una formación y reunión espacio único que ofrece facilidad para médicos y enfermeras.Starting at €5.74
-
TransDigm in 2017: The Beginning of the End or the End of the Beginning?
Esty, Benjamin C.; Fisher, DanielCase HBS-720422-EStrategyTransDigm was a highly acquisitive company that manufactured a wide range of highly engineered aerospace parts for both military and commercial customers. Over the ten years ending in 2016, its stock price had increase ten times, and both EBITDA and revenues had grown at compound annual rates in excess of 20%. But in early 2017, investors, customers, and government officials began to question the implementation, sustainability, and ethics of the ...Starting at €8.20
-
Terumo (A)
Godes, David B.; Egawa, Masako; Yamazaki, MayukaCase HBS-508068-EMarketingTo maximize their effectiveness, color cases should be printed in color. Terumo faces two challenges: how to sell its catheter products in the U.S. and its new "Solution Pack" in its domestic market, Japan. The case provides rich detail on the firm's evolution from a manufacturer of thermometers to a seller of commodity products like syringes to a diversified firm offering a range of advanced products-catheters and graphs, for example-in addition...Starting at €8.20
-
Terumo (B)
Godes, David B.; Egawa, Masako; Yamazaki, MayukaCase HBS-508069-EMarketingThis case provides an update on the firm's decision regarding its U.S. sales strategy for its catheter products and the progress of Solution Pack.Starting at €5.74
-
Gillette: Cutting Prices to Regain Share
Esty, Benjamin C.; Fisher, DanielCase HBS-720378-EStrategyAfter losing market share to low-priced competitors such as Harry's and Dollar Shave Club for several years, Gillette decided to fight back by launching new products and increasing advertising. When these efforts failed to stem the losses, Gillette decided to cut the prices on its razors and blades in April 2017. Bonnie Herzog, an equity analyst at Wells Fargo, must assess how the recently announced price cuts are likely to affect Gillette's earn...Starting at €8.20
-
Fixing Facebook: Fake News, Privacy, and Platform Governance
Yoffie, David B.; Fisher, DanielCase HBS-720400-EStrategyMark Zuckerberg founded Facebook based on the idea that connecting people was a fundamentally good thing-and a way to turn a handsome profit. But from the beginning, Facebook received criticism both for how it handled user privacy and how it curated user-generated content. These two issues coalesced in the aftermath of the 2016 United States presidential election, after Facebook's role in the spread of political misinformation and the leak of Fac...Starting at €8.20
-
Fixing Facebook: Fake News, Privacy, and Platform Governance, Teaching Note
Yoffie, David B.; Fisher, DanielTeaching Note HBS-720417-EStrategyTeaching note for case 720400.Starting at €0.00
-
Intellectual Ventures Update 2020
Yoffie, David B.; Fisher, DanielCase HBS-720438-EStrategyAfter raising $6 billion and buying 60,000 patents, Intellectual Venture was confronted with a changing legal environment. A number of important legal decision, including the Supreme Court's so-called "Alice" decision, IV had to shift strategy. IV sold off a substantial portion of its IP portfolio, and refocused its efforts on trying to innovate, using its acquired technologies.Starting at €8.20
-
United Technologies: Are the Parts Worth More Than the Whole
Esty, Benjamin C.; Fisher, DanielCase HBS-220018-EFinanceAfter spending more than 50 years creating a diversified industrial conglomerate that Fortune Magazine described as "arguably the most profitable conglomerate in America" in 2014, UTC's CEO Greg Hayes was under pressure from activist investors (Dan Loeb aStarting at €8.20
-
Impax Laboratories: Executing Accretive Acquisitions (A)
Esty, Benjamin C.; Fisher, DanielCase HBS-220030-EFinanceImpax Laboratories was a technology-based pharmaceutical company that used a "dual platform" strategy to sell both generic and branded treatments. While Impax had grown organically for most of its history, it was beginning to use major acquisitions for growth. In the early morning of June 21, 2016, the firm issued a press release announcing it was buying a portfolio of generic drugs from Teva for $586 million in cash. The leadership team (CEO, CF...Starting at €8.20